Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome
LIU Chao, AN Wen-Bin, ZHANG Jing-Liao, ZHANG Ran-Ran, SUN Cong-Cong, CHANG Li-Xian, LIU Tian-Feng, ZOU Yao, WANG Hui-Jun, ZHU Xiao-Fan
Department of Pediatric Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
Abstract：Objective To investigate the value of multiparameter flow cytometry (MFC) and flow cytometric scoring system (FCSS) in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome (MDS). Methods A retrospective analysis was performed for the clinical data of 42 children who were diagnosed with MDS. MFC was performed to investigate the phenotype and proportion of each lineage of bone marrow cells. The correlations of FCSS score with MDS type, International Prognostic Scoring System (IPSS) score, and revised IPSS (IPSS-R) score were analyzed. Results Of all the 42 children, 20 (48%) had an increase in abnormal marrow blasts, 19 (45%) had a lymphoid/myeloid ratio of > 1, 14 (33%) had abnormal cross-lineage expression of lymphoid antigens in myeloid cells, 8 (19%) had abnormal CD13/CD16 differentiation antigens, 5 (12%) had abnormal expression of CD56, 3 (7%) had reduced or increased side scatter of granulocytes, 3 (7%) had reduced expression of CD36 in nucleated red blood cells, 2 (5%) had reduced expression of CD71 in nucleated red blood cells, 1 (2%) had absent expression of CD33 in myeloid cells, 1 (2%) had reduced or absent expression of CD11b in granulocytes, and 1 (2%) had absent expression of CD56 and CD14 in monocytes. There were significant differences in the median overall survival time and event-free survival time among the low-, medium-, and high-risk FCSS groups (P < 0.05). Among the low-, medium-, and high-risk FCSS groups,the low-risk FCSS group had the highest 2-year overall survival rate, while there was no significant difference between the medium-and high-risk FCSS groups (P > 0.05). The three groups had a 2-year event-free survival rate of 95%, 60%, and 46% respectively (P < 0.05). FCSS score was positively correlated with MDS type, IPSS score, and IPSS-R score (P < 0.05). Conclusions MFC and FCSS help with the diagnosis and prognostic evaluation of childhood MDS.
LIU Chao,AN Wen-Bin,ZHANG Jing-Liao et al. Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome[J]. CJCP, 2018, 20(10): 819-824.
Haslel H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children[J]. Br J Haemato1, 2011, 154(2):185-195.
[3]
Glaubach T, Robinson LJ, Corey SJ. Pediatric myelodysplastic syndromes, they do exist![J]. J Pediatr Hematol Oncol, 2014, 36(1):1-7.
[4]
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in meylodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation[J]. Blood, 2003, 102(1):394-403.
[7]
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood, 1998, 91(3):1100.
[8]
Geenberg PL, Tuechler H, Schanz J, et a1. Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465.
[9]
Ogata K, Della Porta MG, Malcovati L, et a1. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes:A prospective validation study[J]. Haematologica, 2009, 94(8):1066-1074.
[10]
Baumann I, Niemeyer CM, Bennett JM, et al. Childhood myelodysplastic syndrome[M].//Steven H, Elias C, Nancy LH. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed.WHO Publications Center, 2008:104-107.
[11]
Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for flow cytometry in MDS[J]. Leukemia, 2014, 28(9):1793-1798.
[12]
Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms[J]. Blood, 2008, 111(8):3941-3967.
[13]
Maynadié M, Picard F, Husson B, et a1. 1mmunophenotypic clustering of myelodysplastic syndromes[J]. Blood, 2002, 100(7):2349-2356.
[14]
Mathis S, Chapuis N, Debord C, et a1. Flow cytometric detection of dyserythropoiesis:a sensitive and powerful diagnostic tool for myelodysplastic syndromes[J]. Leukemia, 2013, 27(10):1981-1987.
[15]
Chu SC, Wang TF, Li CC, et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes[J]. Leuk Res, 2011, 35(7):868-873.
